CRISPR-Cas-mediated genome editing technology is revolutionizing fundamental biological and biomedical research, as well as human disease therapy and crop breeding.To date, various genome-editing tools utilizing Cas9, Cas12a, Cas12b, and CasX have been developed.However, these widely used Cas proteins are relatively big nucleases, typically close to or more than 1000 amino acids in length.This poses some challenges for in vivo gene manipulations, such as difficulties in cloning and molecular manipulations, and low efficiency in delivery of the ribonucleoprotein (RNP) complex into the cell nucleus for transgene-free genome editing (Ran et al., 2015).